Latest Drugs, Latest Approval in Histone deacetylase inhibitors

What are Histone deacetylase inhibitors?

Histone deacetylase (HDAC) inhibitors are a group of agents that inhibit the histone deactylase enzymes. During gene expression DNA coils and uncoils around histones. Histone acetylases, acetylate the lysine residues in core histones and histone deactylases remove the acetyl groups from the lysine residues. These actions are important in the regulation of gene expression.

Histone deacetylase inhibitors prevent the deactylation, affect gene expression and causes apoptosis of tumor cells. Histone deacetylase inhibitors are used to treat cutaneous T-cell lymphoma.

Name Updated
Vorinostat (Vorinostat [ vor-in-o-stat ]) 15-Aug-2023
Belinostat (Belinostat [ be-lin-oh-stat ]) 13-Aug-2023
Romidepsin (Romidepsin [ roe-mi-dep-sin ]) 12-Aug-2023
Panobinostat (Panobinostat [ pan-oh-bin-oh-stat ]) 11-Aug-2023
Zolinza (Vorinostat [ vor-in-o-stat ]) 14-Jul-2023
Istodax (Romidepsin [ roe-mi-dep-sin ]) 13-Jul-2023
Farydak (Panobinostat [ pan-oh-bin-oh-stat ]) 13-Jul-2023
Beleodaq (Belinostat [ be-lin-oh-stat ]) 12-Jul-2023